热门资讯> 正文
Theriva Biologics GAAP每股收益为-1.93美元
2025-08-11 20:03
- Theriva Biologics, Inc. Common Stock(TOVX) 0
- Cambria Global Asset Allocation ETF(GAA) 0
- WisdomTree Earnings 500 Fund(EPS) 0
- Theriva Biologics press release (NYSE:TOVX): Q2 GAAP EPS of -$1.93.
- Cash and cash equivalents of $12.1 million as of June 30, 2025, expected cash runway into Q1 2026
More on Theriva Biologics
- Seeking Alpha’s Quant Rating on Theriva Biologics
- Historical earnings data for Theriva Biologics
- Financial information for Theriva Biologics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
